Viemed Healthcare, Inc. Form 4 Filings

VIEMED HEALTHCARE, INC. (VMD) director Sabrina Heltz reported several equity-compensation transactions. On August 19, 2026, 15,029 Restricted Stock Units and 3,757 Phantom Share Units vested and were converted into common shares, with the phantom-share-related common shares simultaneously returned to the company for cash at $8.94 per share. On August 17, 2026, she received new awards of 12,174 RSUs and 3,043 Phantom Share Units, each representing one common share or its cash value and scheduled to vest on the first anniversary of the grant date, with the RSUs expiring on August 17, 2027.

VIEMED HEALTHCARE, INC. (VMD) director Randy E. Dobbs reported a series of equity award events. On August 19, 2026, previously granted 16,763 Restricted Stock Units and 4,191 Phantom Share Units vested and were settled, resulting in the acquisition of corresponding common shares and a simultaneous disposition of 4,191 common shares to the company for cash at $8.94 per share. The phantom units are cash-settled awards economically equivalent to common shares. On August 17, 2026, Dobbs also received a new grant of 16,848 Restricted Stock Units that vest on the first anniversary of the grant date.

For VIEMED HEALTHCARE, INC. (VMD), director Timothy Smokoff reported several equity compensation events. On August 19, 2026, previously granted Restricted Stock Units and Phantom Share Units vested and were exercised or settled into a total of common shares, with 3,757 common shares then returned to the company in a disposition at $8.94 per share. Separately, on August 17, 2026, he received new grants of 12,174 Restricted Stock Units and 3,043 Phantom Share Units, each convertible into an equal number of common shares and scheduled to vest on the first anniversary of the grant date. These transactions were not reported as made under a Rule 10b5-1 trading plan.

Viemed Healthcare Chief Medical Officer William Frazier reported an exercise-and-sell transaction in Viemed Healthcare, Inc. common shares. He exercised stock options for 10,000 Common Shares at $1.81 per share, then sold 10,000 Common Shares in an open-market sale at $11.72 per share on the same date.

After these transactions, Frazier directly holds 73,214 Common Shares and retains 26,261 Stock Options, which are fully vested and expire on January 4, 2028. The filing shows a net reduction of 10,000 common shares in his direct holdings.

VIEMED HEALTHCARE, INC. director Timothy Smokoff reported open-market sales of a total of 20,000 Common Shares of VMD on June 24, 2026. The transactions were executed in five separate trades at prices ranging from $11.41 to $11.56 per share.

Viemed Healthcare, Inc. President Michael Moore reported open-market sales of Common Shares indirectly held through Moore Faster LLC. The LLC sold 31,570 shares on March 18 at a weighted-average price of $9.42, 40,232 shares on March 19 at $9.21, and 65,000 shares on March 20 at $8.77 per share. Footnotes state each reported price is a weighted average for multiple trades in ranges of $9.26–$9.61, $9.04–$9.38, and $8.63–$9.18, respectively. Following these transactions, Moore Faster LLC held 1,585,812 Common Shares indirectly, and Michael Moore also held 189,090 Common Shares directly.

Viemed Healthcare Chief Executive Officer and director Hoyt Casey reported equity compensation-related transactions on common shares dated January 29, 2026. He acquired 39,795 common shares through the vesting and settlement of Restricted Stock Units and 13,265 common shares tied to cash-settled phantom share units.

The company withheld 13,913 common shares at a per-share value of $7.48 to cover Casey’s tax obligations from RSU vesting, and 13,265 common shares were simultaneously disposed of to the company in connection with phantom share settlement. After these transactions, Casey directly owned 350,464 common shares and indirectly held 1,984,943 common shares through Elizabeth Rose Homes LLC.

Viemed Healthcare vice president of sales Jerome Cambre reported equity award vesting and related share movements. On January 29, 2026, 8,619 Restricted Stock Units converted into common shares and 2,873 phantom share units vested into common shares. To cover taxes from RSU vesting, the issuer withheld 2,355 common shares at a per-share value of $7.48, based on the market closing price that day. Following the reported transactions, Cambre directly held 104,088 Viemed common shares.

Viemed Healthcare president Michael Moore reported equity award vesting and related share movements. On January 29, 2026, 26,842 Restricted Stock Units converted into an equal number of common shares, and 8,947 phantom share units vested and were economically settled for common shares before being delivered back to the company for cash.

The issuer withheld 7,342 common shares at $7.48 per share to cover Moore’s tax obligations from the RSU vesting. After these transactions, Moore held 189,090 common shares directly and 1,722,614 common shares indirectly through Moore Faster LLC.

Viemed Healthcare’s General Counsel, Jeremy Trahan, reported equity award vesting and related share movements in company stock. On January 29, 2026, 10,774 restricted stock units converted into the same number of common shares, while 2,939 shares were withheld by the company to cover taxes at a value of $7.48 per share.

The filing also shows 3,591 cash-settled phantom share units vesting, economically equivalent to common shares and settled in cash with matching share movements. After these transactions, Trahan directly holds 46,492 common shares, plus 10,773 restricted stock units and 3,591 phantom share units as continuing equity interests.

Viemed Healthcare, Inc. Chief Medical Officer and director William Frazier reported equity award vesting and related share transactions. On January 29, 2026, 2,334 Restricted Stock Units converted into 2,334 common shares, and 778 phantom share units converted into 778 common shares, both at an exercise price of $0 per share.

To cover tax obligations from the RSU vesting, 802 common shares were withheld and disposed of at $7.48 per share, based on the closing market price on January 29, 2026. After these transactions and related dispositions, Frazier beneficially owned 73,214 common shares directly.

Viemed Healthcare Chief Financial Officer Fitzgerald Trae reported equity award activity on January 29, 2026. A block of 9,794 restricted stock units converted into the same number of common shares, and 3,265 cash-settled phantom share units were settled into common shares under the company’s plans.

To cover tax obligations from the restricted stock vesting, 2,679 common shares were withheld by Viemed at a per‑share value of $7.48. In connection with the phantom share settlement, 3,265 common shares were delivered to and simultaneously surrendered back to the company for cash. After these transactions, Trae directly owned 105,638 common shares.

Viemed Healthcare, Inc. Chief Operating Officer and director William Todd Zehnder reported equity compensation vesting and related tax share dispositions. On January 29, 2026, 26,842 restricted stock units converted into an equal number of common shares, and 8,948 cash-settled phantom share units vested, each economically equivalent to one common share.

The company withheld 11,368 common shares at $7.48 per share and a further 8,948 common shares at the same price to cover tax obligations tied to these awards. After these transactions, Zehnder directly owned 390,309 common shares of Viemed Healthcare.

Viemed Healthcare Chief Medical Officer reports equity award vesting and related share transactions. Director and Chief Medical Officer William Frazier reported the vesting of 3,401 Restricted Stock Units (each equal to one common share) and 850 cash-settled phantom share units on January 21, 2026. After these transactions, he directly owned 71,682 common shares.

To cover tax obligations from the RSU vesting, 1,169 common shares were withheld by the company at a per‑share value of $7.49, and 850 common shares were simultaneously acquired and disposed of in connection with settlement of phantom share units for cash. Following the derivative activity, he held 6,800 Restricted Stock Units and 1,700 phantom share units, which were originally granted on January 21, 2025 and vest in three equal annual installments.

Viemed Healthcare President Michael Moore reported equity award vesting and related share movements. On January 21, 2026, 34,214 Restricted Stock Units (RSUs) were converted into an equal number of common shares, and 8,554 phantom share units under the company’s Phantom Share Unit Plan vested, each economically equivalent to one common share.

To cover taxes from RSU vesting, 9,358 common shares were withheld by Viemed Healthcare at a per share value of $7.49, and 8,554 common shares related to the phantom share settlement were disposed of to the company at the same value. After these transactions, Moore directly held 169,590 common shares, 68,428 RSUs and 17,107 phantom share units, and also had an indirect interest in 1,722,614 common shares held by Moore Faster LLC.

Viemed Healthcare, Inc. Chief Executive Officer and director Hoyt Casey reported equity compensation activity and related share movements. On January 21, 2026, 49,597 Restricted Stock Units and 12,400 phantom share units vested, each unit representing the economic equivalent of one common share. In connection with the RSU vesting, the company withheld 13,565 common shares at $7.49 per share to satisfy tax obligations, and 12,400 common shares tied to phantom units were delivered back to the company for cash settlement.

After these transactions, Casey directly holds 324,582 common shares, along with 99,194 RSUs and 24,798 phantom share units. He also has an indirect holding of 1,984,943 common shares through Elizabeth Rose Homes LLC.

Viemed Healthcare, Inc. insider William Todd Zehnder, the Chief Operating Officer and a director, reported equity compensation transactions on 01/21/2026. He exercised 117,548 Restricted Stock Units (RSUs), each converting into one common share, and his directly held common shares increased as part of this vesting.

To cover related tax obligations from the RSU vesting, the company withheld 35,075 common shares at a per‑share value of $7.49, based on the market closing price on January 21, 2026. The filing also shows vesting and settlement of 8,554 cash‑settled phantom share units, economically equivalent to common shares, which resulted in both an acquisition and disposition of the same number of common shares for cash.

After these transactions, Zehnder directly owned 374,835 common shares, along with 235,094 RSUs and 17,107 phantom share units that remain outstanding and continue to represent future or cash‑settled economic exposure to Viemed common shares.

Viemed Healthcare Chief Financial Officer Fitzgerald Trae reported equity award activity involving restricted stock units, phantom share units, and common shares on January 21, 2026. A block of 13,317 restricted stock units vested and converted into common shares, with 4,246 of those shares withheld by the company to cover taxes at a per-share value of $7.49, leaving 98,523 common shares directly held after the transactions. In addition, 3,329 cash-settled phantom share units vested under the company’s Phantom Share Unit Plan, which were economically equivalent to common shares and were settled in cash through a matched acquisition and disposition of 3,329 underlying common shares. Following these events, Trae held 26,632 restricted stock units and 6,658 phantom share units, each unit tied to one common share.

Viemed Healthcare Vice President of Sales Cambre Jerome reported equity award activity and related share transactions. On January 21, 2026, 11,719 Restricted Stock Units (RSUs) vested and were settled into an equal number of common shares, consistent with each RSU representing one common share. To cover taxes from this vesting, the issuer withheld 3,827 common shares at a per-share value of $7.49, based on the market closing price for that date.

The filing also shows vesting of 2,930 cash-settled phantom share units granted under Viemed’s Phantom Share Unit Plan, which are economically equivalent to common shares. The settlement is reported as an exchange of phantom shares for the underlying common shares and a simultaneous disposition of those common shares back to the company for cash. After these transactions, Jerome directly beneficially owned 97,824 common shares, as well as 23,436 RSUs and 5,859 phantom share units that remain outstanding.

Viemed Healthcare General Counsel Jeremy Trahan reported multiple equity-related transactions on January 21, 2026. He exercised and vested 14,648 Restricted Stock Units, each converting into one common share, bringing his directly held common shares at one point to 43,440.

To cover taxes from the RSU vesting, the company withheld 4,783 common shares at a per-share value of $7.49, leaving Trahan with 38,657 common shares after that step. He also had 3,662 cash-settled phantom share units vest under the Phantom Share Unit Plan, economically equivalent to common shares, with settlement reported as both acquisition and disposition of the related common shares.

Following these transactions, Trahan held 29,296 Restricted Stock Units and 7,324 phantom share units, both scheduled to vest in equal annual installments through January 21, 2028, aligning a portion of his compensation with Viemed Healthcare’s share performance over time.

Viemed Healthcare CEO Hoyt Casey reported multiple equity transactions. On January 17, 2026, previously granted awards vested, resulting in the acquisition of 40,068 common shares and 10,017 common shares tied to phantom share vesting. To cover tax obligations and settle cash awards, 12,118 shares were withheld by the company and 10,017 shares were disposed of at $7.33 per share.

Following these transactions, Casey directly held 288,550 common shares and also reported indirect beneficial ownership of 1,984,943 common shares held by Elizabeth Rose Homes LLC. On January 19, 2026, he received new grants of 172,155 restricted stock units and 43,039 phantom share units, each representing the value of one common share and scheduled to vest in three equal annual installments beginning one year after the grant dates.

Viemed Healthcare, Inc. reported an insider equity award for Chief Medical Officer and director William Frazier. On January 19, 2026, he received 11,690 Restricted Stock Units (RSUs), each representing a contingent right to one common share. These RSUs vest in three equal annual installments beginning on the first anniversary of the grant date.

On the same date, he was also granted 2,922 Phantom Share Units under the company’s Phantom Share Unit Plan. Each phantom share represents the right to receive the cash value of one common share, determined based on the share price on the vesting date, and also vests in three equal annual installments starting one year after the grant date.

Viemed Healthcare President Michael Moore reported equity compensation and related share settlements. On January 19, 2026, he received 118,759 Restricted Stock Units and 29,690 phantom share units, each representing the value of one common share and vesting in three equal annual installments beginning on the first anniversary of the grant date. Earlier, on January 17, 2026, previously granted RSUs and phantom units vested, resulting in the acquisition and disposition of matching common shares, including 8,548 shares withheld at $7.33 per share to cover taxes. After these transactions, Moore directly beneficially owned 144,734 common shares and indirectly owned 1,722,614 common shares through Moore Faster LLC.

Viemed Healthcare, Inc. reported insider equity activity for Chief Operating Officer and director William Todd Zehnder. On January 19, 2026, he received 118,759 Restricted Stock Units (RSUs) and 29,690 phantom share units, each tied to one common share or its cash value and vesting in three equal annual installments beginning one year after the grant date.

On January 17, 2026, previously granted awards from January 17, 2023 partially vested. This led to the acquisition of 26,939 common shares from RSUs and 6,735 common shares tied to cash-settled phantom shares, followed by dispositions back to the company. The filing also shows 8,550 common shares withheld at $7.33 per share to cover taxes. After these transactions, Zehnder directly held 292,362 common shares, plus the new RSU and phantom unit balances.

Viemed Healthcare vice president of sales Jerome Cambre reported equity compensation and related tax transactions in company stock. On January 17, 2026, previously granted awards vested, resulting in the acquisition of 8,525 common shares from restricted stock units and 2,132 common shares tied to phantom share units. To cover taxes from the vesting, 2,784 shares and a separate 2,132-share block were disposed of at a per-share value of $7.33, leaving Cambre with 89,932 common shares held directly.

On January 19, 2026, Cambre received new grants of 40,676 restricted stock units and 10,169 phantom share units. Each restricted stock unit represents a contingent right to receive one common share, and both the new RSU and phantom share awards vest in three equal annual installments beginning on the first anniversary of their respective grant dates.

Viemed Healthcare (VMD) Chief Financial Officer Trae Fitzgerald reported a mix of equity awards vesting, tax withholding, and new grants. On January 17, 2026, 9,590 restricted stock units and 2,397 cash-settled phantom share units vested, each unit economically equal to one common share. To cover taxes from RSU vesting, 3,132 common shares were withheld at $7.33 per share, based on the January 16, 2026 closing price, and 2,397 common shares were delivered back to the company in connection with phantom share settlement. After these transactions, Fitzgerald directly held 89,452 common shares.

On January 19, 2026, Fitzgerald received new equity awards of 46,662 restricted stock units and 11,666 phantom share units, each with a stated value of $0 per unit on grant and scheduled to vest in three equal annual installments beginning on the first anniversary of the grant date.

Viemed Healthcare General Counsel Jeremy Trahan reported multiple equity compensation transactions. On January 17, 2026, 4,884 restricted stock units and 1,221 cash-settled phantom share units vested, resulting in the acquisition of the same number of common shares. To cover tax obligations tied to the RSU vesting, 1,595 common shares were withheld at a per share value of $7.33, leaving 28,792 common shares held directly after the transactions.

On January 19, 2026, Trahan was granted 50,360 new restricted stock units and 12,590 phantom share units. Both awards vest in three equal annual installments beginning on the first anniversary of their grant date. Each RSU represents a right to receive one common share, while each phantom share represents the cash value of one common share on the vesting date.